- Home
- CODX vs RLYB Comparison
CODX vs RLYB Comparison
Compare CODX & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODX
- RLYB
- Stock Information
- Founded
- CODX 2013
- RLYB 2018
- Country
- CODX United States
- RLYB United States
- Employees
- CODX N/A
- RLYB N/A
- Industry
- CODX Medical/Dental Instruments
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- CODX Health Care
- RLYB Health Care
- Exchange
- CODX Nasdaq
- RLYB Nasdaq
- Market Cap
- CODX 22.0M
- RLYB 25.0M
- IPO Year
- CODX 2017
- RLYB 2021
- Fundamental
- Price
- CODX $0.35
- RLYB $0.30
- Analyst Decision
- CODX Hold
- RLYB Hold
- Analyst Count
- CODX 1
- RLYB 5
- Target Price
- CODX $1.00
- RLYB $11.50
- AVG Volume (30 Days)
- CODX 163.5K
- RLYB 203.8K
- Earning Date
- CODX 05-08-2025
- RLYB 05-08-2025
- Dividend Yield
- CODX N/A
- RLYB N/A
- EPS Growth
- CODX N/A
- RLYB N/A
- EPS
- CODX N/A
- RLYB N/A
- Revenue
- CODX $3,915,160.00
- RLYB $636,000.00
- Revenue This Year
- CODX N/A
- RLYB N/A
- Revenue Next Year
- CODX N/A
- RLYB N/A
- P/E Ratio
- CODX N/A
- RLYB N/A
- Revenue Growth
- CODX N/A
- RLYB N/A
- 52 Week Low
- CODX $0.28
- RLYB $0.22
- 52 Week High
- CODX $2.23
- RLYB $2.00
- Technical
- Relative Strength Index (RSI)
- CODX 42.44
- RLYB 32.68
- Support Level
- CODX $0.32
- RLYB $0.28
- Resistance Level
- CODX $0.38
- RLYB $0.31
- Average True Range (ATR)
- CODX 0.05
- RLYB 0.03
- MACD
- CODX 0.01
- RLYB 0.01
- Stochastic Oscillator
- CODX 60.87
- RLYB 36.22
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.